ABBV-CLS-7262

Calico’s and AbbVie’s orally bioavailable eIF2B activator prodrug ABBV-CLS-7262 (fosigotifator) is being developed as a potential treatment for Vanishing White Matter disease (VWM), an ultra-rare progressive leukoencephalopathy. Accepted into the FDA’s START Pilot Program, ABBV-CLS-7262 is currently in an open-label Ph. I/II trial for adults and pediatrics with VWM disease and a randomized, double-blind Ph. I trial in patients with Amyotrophic Lateral Sclerosis (ALS).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.